137 related articles for article (PubMed ID: 27196770)
21. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
[TBL] [Abstract][Full Text] [Related]
22. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
23. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
24. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
[TBL] [Abstract][Full Text] [Related]
25. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.
Li H; Liu Y; Jiao Y; Guo A; Xu X; Qu X; Wang S; Zhao J; Li Y; Cao Y
Oncol Rep; 2016 Jan; 35(1):343-51. PubMed ID: 26498391
[TBL] [Abstract][Full Text] [Related]
27. Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
Ishida CT; Zhang Y; Bianchetti E; Shu C; Nguyen TTT; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Prabhu VV; Allen JE; Siegelin MD
Clin Cancer Res; 2018 Nov; 24(21):5392-5406. PubMed ID: 30037819
[No Abstract] [Full Text] [Related]
28. Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells.
Echizenya S; Ishii Y; Kitazawa S; Tanaka T; Matsuda S; Watanabe E; Umekawa M; Terasaka S; Houkin K; Hatta T; Natsume T; Maeda Y; Watanabe SI; Hagiwara S; Kondo T
Neuro Oncol; 2020 Feb; 22(2):229-239. PubMed ID: 31499527
[TBL] [Abstract][Full Text] [Related]
29. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
30. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
[TBL] [Abstract][Full Text] [Related]
31. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
33. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
34. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
35. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis.
Zhang R; Banik NL; Ray SK
Neurochem Res; 2007 Dec; 32(12):2194-202. PubMed ID: 17616812
[TBL] [Abstract][Full Text] [Related]
36. Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival.
Kang YJ; Balter B; Csizmadia E; Haas B; Sharma H; Bronson R; Yan CT
Nat Commun; 2017 Jan; 8():14013. PubMed ID: 28094268
[TBL] [Abstract][Full Text] [Related]
37. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
[TBL] [Abstract][Full Text] [Related]
38. Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
Watanabe T; Ohtani T; Aihara M; Ishiuchi S
J Neurosurg; 2013 Apr; 118(4):838-45. PubMed ID: 23311938
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Avramis IA; Christodoulopoulos G; Suzuki A; Laug WE; Gonzalez-Gomez I; McNamara G; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2002 Dec; 50(6):479-89. PubMed ID: 12451475
[TBL] [Abstract][Full Text] [Related]
40. Culture dimensionality influences the resistance of glioblastoma stem-like cells to multikinase inhibitors.
Fernandez-Fuente G; Mollinedo P; Grande L; Vazquez-Barquero A; Fernandez-Luna JL
Mol Cancer Ther; 2014 Jun; 13(6):1664-72. PubMed ID: 24723451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
